Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.

doi:10.1080/0284186X.2017.1332780

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.

Acta oncologica (Stockholm, Sweden) - 1 Dec 2017

Malmström Annika, Poulsen Hans Skovgaard, Grønberg Bjørn Henning, Stragliotto Giuseppe, Hansen Steinbjørn, Asklund Thomas, Holmlund Birgitta, Łysiak Małgorzata, Dowsett Joseph, Kristensen Bjarne Winther, Söderkvist Peter, Rosell Johan, Henriksson Roger

Abstract excerpt

INTRODUCTION: A pilot study of temozolomide (TMZ) given before radiotherapy (RT) for anaplastic astrocytoma (AA) and glioblastoma (GBM) resulted in prolonged survival compared to historical controls receiving RT alone. We therefore investigated neoadjuvant TMZ (NeoTMZ) in a randomized trial. During enrollment, concomitant and adjuvant radio-chemotherapy with TMZ became standard treatment. The trial was amended to...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Astrocytoma

Share to Dacarbazine

Share to DNA Modification Methylases

Share to Neurosurgical Procedures

Share to Radiotherapy, Adjuvant

Share to Temozolomide

Share to X-linked Nuclear Protein

Source

Open in PubMed

Identifiers

PMID: 28675067
DOI: 10.1080/0284186X.2017.1332780

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial.PMID 28675067Read ↗

The impact of concurrent temozolomide with adjuvant radiation and IDH mutation status among patients with anaplastic astrocytoma.Semantic proximity Read ↗

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.Semantic proximity Read ↗

IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy.Semantic proximity Read ↗

Impact of delays in initiating postoperative chemoradiation while determining the MGMT promoter-methylation statuses of patients with primary glioblastomaSemantic proximity Read ↗

Old Does Not Necessarily Mean Worse: Standard 6-Week Chemoradiation For Elderly Patients (≥ 70 Years) With Newly Diagnosed GlioblastomaSemantic proximity Read ↗

Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.Semantic proximity Read ↗

Accelerated Hyper-Versus Normofractionated Radiochemotherapy with Temozolomide in Patients with Glioblastoma: A Multicenter Retrospective Analysis.Semantic proximity Read ↗

Temozolomide and 13-cis retinoic acid in patients with anaplastic gliomas: a prospective single-arm monocentric phase-II study (RNOP-05).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.